INDV1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
SUBLOCADE-led Growth And ProfitabilityStrong recent growth in both company revenue and SUBLOCADE sales indicates expanding demand for Indivior’s core treatment franchise. Record sales alongside improved profitability can support continued investment, reinforce commercial scale, and strengthen the company’s earnings base over the next several quarters.
SUBLOCADE Market Position And IP DurabilityA high, stable market share combined with long-dated patent protection provides SUBLOCADE with meaningful competitive support. The product’s established position and extended intellectual-property runway can help preserve branded revenue, sustain pricing power, and support durable adoption.
Merger Scale And Cost SynergiesThe proposed combination would broaden Indivior’s CNS portfolio and increase operating scale across multiple therapeutic areas. Management’s quantified synergy target offers a concrete route to improved efficiency, while the larger platform could support investment in growth products and future business development.
Bears Say
Weak Cash ConversionNegative operating and free cash flow despite positive TTM net income signals inconsistent earnings conversion into cash. This volatility can limit internally funded investment, increase reliance on balance-sheet flexibility, and make the business less resilient if working-capital demands or operating needs rise.
Negative Shareholders’ EquityPersistently negative equity weakens the company’s capital structure and reduces the balance-sheet cushion available during operating setbacks. Even with currently low reported debt, the equity deficit can amplify downside risk and constrain financial flexibility through a downturn or major investment cycle.
Merger Leverage And Execution RiskThe merger introduces materially greater absolute debt while requiring successful approvals, integration, and synergy delivery. Execution problems could delay benefits or weaken commercial momentum, and the higher debt burden may reduce flexibility if integration costs, competitive pressure, or investment needs exceed expectations.
Indivior News
INDV1 FAQ
What was Indivior PLC’s price range in the past 12 months?
Currently, no data Available
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is $69.74B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Oct 29, 2026 which is in 43 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Aug 03, 2026. The company reported $19.589 earnings per share for the quarter, beating the consensus estimate of $14.803 by $4.787.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 17.99.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 118,013,650 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of $19.589 in its last earnings report, beating expectations of $14.803. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in MX:INDV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Indivior Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$822.93 (― Upside)
$822.93 (― Upside)
Blogger Sentiment
Bullish
MX:INDV1 Sentiment 83%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
47.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Indivior PLC
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
INDV1 Company Deck
INDV1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presents a constructive and optimistic view of the merger: management emphasized scale, a diversified portfolio (~$2.2B pro forma revenue), strong pro forma profitability (adjusted EBITDA $888M; ~41% margin), and $125M of near-term cost synergies, while retaining balance sheet strength and highlighting SUBLOCADE as a durable, large growth driver (~44% of revenue) supported by IP and commercial momentum. Noted risks include revenue concentration in SUBLOCADE, increased pro forma net debt (~$878M, ~1x leverage), absence of quantified revenue synergies, and standard integration and regulatory execution risks. On balance, the positives (scale, margins, synergies, product durability) outweigh the lowlights.View all MX:INDV1 earnings summaries